DEFINING TOMORROW'S VASCULAR STRATEGIES
×
Register now to R3i !
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
The Initiative

Prof. Tony Gotto

Prof. Tony Gotto
Cornell University,
New York, USA
 
Short Narrative Biography
 

Antonio M. Gotto, Jr., MD, DPhil, is Dean Emeritus and Co-Chairman of the Board of Overseers of Weill Cornell Medical College in New York, New York, where he is also the Lewis Thomas University Professor. In addition, Dr. Gotto is Vice President and Provost for Medical Affairs Emeritus of Cornell University. From 1997-2011, Dr. Gotto was the Stephen and Suzanne Weiss Dean at Weill Cornell and Provost for Medical Affairs at Cornell University.  

Dr. Gotto’s postgraduate work included doctoral studies at Oxford University in England, as a Rhodes Scholar, and residency training at the Massachusetts General Hospital in Boston, Massachusetts.  In the field of atherosclerosis, his basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I); they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. Dr. Gotto has played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk for heart disease.
 
A lifelong supporter of educational efforts aimed at cardiovascular risk reduction, Dr. Gotto has been National President of the American Heart Association and President of the International Atherosclerosis Society. He is a member of the Institute of Medicine and the American Academy of Arts and Sciences.  Dr. Gotto has contributed more than 500 scholarly articles and books to the medical literature, and he is coauthor of the Living Heart series of books that explain the origins and treatment of cardiovascular disease to the general public.